Interplay between Janus kinase/signal transducer and activator of transcription signaling activated by type I interferons and viral antagonism

Frontiers in Immunology

Volumn 8, Issue DEC, 2017, Pages

  Nan, Yuchen ^a,b   Wu, Chunyan ^a   Zhang, Yan Jin ^b  

^a NORTHWEST A F UNIVERSITY   (China)

^b University of Maryland   (United States)

Author keywords

Interferons; Janus kinase signal transducer and activator of transcription signaling; Janus kinases; Signal transducer and activator of transcriptions; Viral antagonism; Viral attenuation

Indexed keywords

INTERFERON; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 3; INTERLEUKIN 27; INTERLEUKIN 6; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; TYROSINE;

ACETYLATION; ANTIBIOSIS; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; JAK-STAT SIGNALING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; UPREGULATION; VIRUS INFECTION; VIRUS INTERFERENCE; VIRUS PATHOGENESIS; VIRUS VIRULENCE;

EID: 85037635145     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01758     Document Type: Review

References (247)

1. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol (2012) 12:125-35. doi:10.1038/nri3133
2. Nan Y, Nan G, Zhang YJ. Interferon induction by RNA viruses and antagonism by viral pathogens. Viruses (2014) 6:4999-5027. doi:10.3390/v6124999
3. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2004) 75:163-89. doi:10.1189/jlb.0603252
4. Fensterl V, Sen GC. Interferons and viral infections. Biofactors (2009) 35:14-20. doi:10.1002/biof.6
5. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 45:164-71. doi:10.1038/ng.2521
6. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol (2004) 22:929-79. doi:10.1146/annurev.immunol.22.012703.104622
7. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev (2004) 202:8-32. doi:10.1111/j.0105-2896.2004.00204.x
8. Schindler C, Shuai K, Prezioso VR, Darnell JE Jr. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science (1992) 257:809-13. doi:10.1126/science.1496401
9. Larner AC, Jonak G, Cheng YS, Korant B, Knight E, Darnell JE Jr. Transcriptional induction of two genes in human cells by beta interferon. Proc Natl Acad Sci U S A (1984) 81:6733-7. doi:10.1073/pnas.81.21.6733
10. Levy DE, Kessler DS, Pine R, Reich N, Darnell JE Jr. Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control. Genes Dev (1988) 2:383-93. doi:10.1101/gad.2.4.383
11. Veals SA, Schindler C, Leonard D, Fu XY, Aebersold R, Darnell JE Jr, et al. Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol Cell Biol (1992) 12:3315-24. doi:10.1128/MCB.12.8.3315
12. Shuai K, Stark GR, Kerr IM, Darnell JE Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science (1993) 261:1744-6. doi:10.1126/science.7690989
13. Reich NC, Pfeffer LM. Evidence for involvement of protein kinase C in the cellular response to interferon alpha. Proc Natl Acad Sci U S A (1990) 87:8761-5. doi:10.1073/pnas.87.22.8761
14. O'shea JJ. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity (1997) 7:1-11. doi:10.1016/S1074-7613(00)80505-1
15. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol (2002) 3:651-62. doi:10.1038/nrm909
16. Girault JA, Labesse G, Mornon JP, Callebaut I. The N-termini of FAK and JAKs contain divergent band 4.1 domains. Trends Biochem Sci (1999) 24:54-7. doi:10.1016/S0968-0004(98)01331-0
17. Haan C, Kreis S, Margue C, Behrmann I. Jaks and cytokine receptors-an intimate relationship. Biochem Pharmacol (2006) 72:1538-46. doi:10.1016/j.bcp.2006.04.013
18. Lupardus PJ, Ultsch M, Wallweber H, Bir Kohli P, Johnson AR, Eigenbrot C. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition. Proc Natl Acad Sci U S A (2014) 111:8025-30. doi:10.1073/pnas.1401180111
19. Chowdhury FZ, Farrar JD. STAT2: a shape-shifting anti-viral super STAT. JAKSTAT (2013) 2:e23633. doi:10.4161/jkst.23633
20. Steen HC, Gamero AM. STAT2 phosphorylation and signaling. JAKSTAT (2013) 2:e25790. doi:10.4161/jkst.25790
21. Azam M, Lee C, Strehlow I, Schindler C. Functionally distinct isoforms of STAT5 are generated by protein processing. Immunity (1997) 6:691-701. doi:10.1016/S1074-7613(00)80445-8
22. Sherman MA, Secor VH, Brown MA. IL-4 preferentially activates a novel STAT6 isoform in mast cells. J Immunol (1999) 162:2703-8
23. Hoey T, Zhang S, Schmidt N, Yu Q, Ramchandani S, Xu X, et al. Distinct requirements for the naturally occurring splice forms Stat4alpha and Stat4beta in IL-12 responses. EMBO J (2003) 22:4237-48. doi:10.1093/emboj/cdg393
24. Maritano D, Sugrue ML, Tininini S, Dewilde S, Strobl B, Fu X, et al. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol (2004) 5:401-9. doi:10.1038/ni1052
25. Caldenhoven E, Van Dijk TB, Solari R, Armstrong J, Raaijmakers JA, Lammers JW, et al. STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J Biol Chem (1996) 271:13221-7. doi:10.1074/jbc.271.22.13221
26. Moriggl R, Gouilleux-Gruart V, Jahne R, Berchtold S, Gartmann C, Liu X, et al. Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype. Mol Cell Biol (1996) 16:5691-700. doi:10.1128/MCB.16.10.5691
27. Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci (2000) 25:496-502. doi:10.1016/S0968-0004(00)01624-8
28. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 5:375-86. doi:10.1038/nri1604
29. Sekimoto T, Imamoto N, Nakajima K, Hirano T, Yoneda Y. Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J (1997) 16:7067-77. doi:10.1093/emboj/16.23.7067
30. Nardozzi J, Wenta N, Yasuhara N, Vinkemeier U, Cingolani G. Molecular basis for the recognition of phosphorylated STAT1 by importin alpha5. J Mol Biol (2010) 402:83-100. doi:10.1016/j.jmb.2010.07.013
31. Bancerek J, Poss ZC, Steinparzer I, Sedlyarov V, Pfaffenwimmer T, Mikulic I, et al. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity (2013) 38:250-62. doi:10.1016/j.immuni.2012.10.017
32. Miyakoshi M, Yamamoto M, Tanaka H, Ogawa K. Serine 727 phosphorylation of STAT3: an early change in mouse hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine. Mol Carcinog (2014) 53:67-76. doi:10.1002/mc.21949
33. Majoros A, Platanitis E, Kernbauer-Holzl E, Rosebrock F, Muller M, Decker T. Canonical and non-canonical aspects of JAK-STAT signaling: lessons from interferons for cytokine responses. Front Immunol (2017) 8:29. doi:10.3389/fimmu.2017.00029
34. Pfeffer SR, Fan M, Du Z, Yang CH, Pfeffer LM. Unphosphorylated STAT3 regulates the antiproliferative, antiviral, and gene-inducing actions of type I interferons. Biochem Biophys Res Commun (2017) 490:739-45. doi:10.1016/j.bbrc.2017.06.111
35. Ruvolo V, Navarro L, Sample CE, David M, Sung S, Swaminathan S. The Epstein-Barr virus SM protein induces STAT1 and interferon-stimulated gene expression. J Virol (2003) 77:3690-701. doi:10.1128/JVI.77.6.3690-3701.2003
36. Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, et al. IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J (2013) 32:2751-63. doi:10.1038/emboj.2013.203
37. Sung PS, Cheon H, Cho CH, Hong SH, Park DY, Seo HI, et al. Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness. Proc Natl Acad Sci U S A (2015) 112:10443-8. doi:10.1073/pnas.1513341112
38. Wang W, Yin Y, Xu L, Su J, Huang F, Wang Y, et al. Unphosphorylated ISGF3 drives constitutive expression of interferon-stimulated genes to protect against viral infections. Sci Signal (2017) 10(476):eaah4248. doi:10.1126/scisignal.aah4248
39. Cui X, Zhang L, Luo J, Rajasekaran A, Hazra S, Cacalano N, et al. Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer. Oncogene (2007) 26:4253-60. doi:10.1038/sj.onc.1210222
40. Testoni B, Vollenkle C, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. Chromatin dynamics of gene activation and repression in response to interferon alpha (IFN(alpha)) reveal new roles for phosphorylated and unphosphorylated forms of the transcription factor STAT2. J Biol Chem (2011) 286:20217-27. doi:10.1074/jbc.M111.231068
41. Butturini E, Gotte G, Dell'orco D, Chiavegato G, Marino V, Canetti D, et al. Intermolecular disulfide bond influences unphosphorylated STAT3 dimerization and function. Biochem J (2016) 473:3205-19. doi:10.1042/BCJ20160294
42. Decker T. Emancipation from transcriptional latency: unphosphorylated STAT5 as guardian of hematopoietic differentiation. EMBO J (2016) 35:555-7. doi:10.15252/embj.201693974
43. Rodrigues BR, Queiroz-Hazarbassanov N, Lopes MH, Bleggi-Torres LF, Suzuki S, Cunha IW, et al. Nuclear unphosphorylated STAT3 correlates with a worse prognosis in human glioblastoma. Pathol Res Pract (2016) 212:517-23. doi:10.1016/j.prp.2016.03.001
44. Yu Y, Wang R, Nan Y, Zhang L, Zhang Y. Induction of STAT1 phosphorylation at serine 727 and expression of proinflammatory cytokines by porcine reproductive and respiratory syndrome virus. PLoS One (2013) 8:e61967. doi:10.1371/journal.pone.0061967
45. Zouein FA, Altara R, Chen Q, Lesnefsky EJ, Kurdi M, Booz GW. Pivotal importance of STAT3 in protecting the heart from acute and chronic stress: new advancement and unresolved issues. Front Cardiovasc Med (2015) 2:36. doi:10.3389/fcvm.2015.00036
46. Haq R, Halupa A, Beattie BK, Mason JM, Zanke BW, Barber DL. Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases. J Biol Chem (2002) 277:17359-66. doi:10.1074/jbc.M201842200
47. Ramsauer K, Sadzak I, Porras A, Pilz A, Nebreda AR, Decker T, et al. p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation. Proc Natl Acad Sci U S A (2002) 99:12859-64. doi:10.1073/pnas.192264999
48. Gao J, Fan M, Xiang G, Wang J, Zhang X, Guo W, et al. Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells. Cell Death Dis (2017) 8:e2765. doi:10.1038/cddis.2017.159
49. Majoros A, Platanitis E, Szappanos D, Cheon H, Vogl C, Shukla P, et al. Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1. EMBO Rep (2016) 17:367-82. doi:10.15252/embr.201540726
50. Putz EM, Gotthardt D, Hoermann G, Csiszar A, Wirth S, Berger A, et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep (2013) 4:437-44. doi:10.1016/j.celrep.2013.07.012
51. Putz EM, Gotthardt D, Sexl V. STAT1-S727-the license to kill. Oncoimmunology (2014) 3:e955441. doi:10.4161/21624011.2014.955441
52. Rzymski T, Mikula M, Zylkiewicz E, Dreas A, Wiklik K, Golas A, et al. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget (2017) 8:33779-95. doi:10.18632/oncotarget.16810
53. Steen HC, Kotredes KP, Nogusa S, Harris MY, Balachandran S, Gamero AM. Phosphorylation of STAT2 on serine-734 negatively regulates the IFN-alpha-induced antiviral response. J Cell Sci (2016) 129:4190-9. doi:10.1242/jcs.185421
54. Ho J, Pelzel C, Begitt A, Mee M, Elsheikha HM, Scott DJ, et al. STAT2 is a pervasive cytokine regulator due to its inhibition of STAT1 in multiple signaling pathways. PLoS Biol (2016) 14:e2000117. doi:10.1371/journal.pbio.2000117
55. Blaszczyk K, Olejnik A, Nowicka H, Ozgyin L, Chen YL, Chmielewski S, et al. STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. Biochem J (2015) 466:511-24. doi:10.1042/BJ20140644
56. Cheon H, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A (2009) 106:9373-8. doi:10.1073/pnas.0903487106
57. Zimmerman MA, Rahman NT, Yang D, Lahat G, Lazar AJ, Pollock RE, et al. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. Cancer Res (2012) 72:4724-32. doi:10.1158/0008-5472.CAN-12-1347
58. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res (2012) 40:D261-70. doi:10.1093/nar/gkr1122
59. Shiromizu T, Adachi J, Watanabe S, Murakami T, Kuga T, Muraoka S, et al. Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the chromosome-centric human proteome project. J Proteome Res (2013) 12:2414-21. doi:10.1021/pr300825v
60. Steen HC, Nogusa S, Thapa RJ, Basagoudanavar SH, Gill AL, Merali S, et al. Identification of STAT2 serine 287 as a novel regulatory phosphorylation site in type I interferon-induced cellular responses. J Biol Chem (2013) 288:747-58. doi:10.1074/jbc.M112.402529
61. Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A. SOCS, inflammation, and cancer. JAKSTAT (2013) 2:e24053. doi:10.4161/jkst.24053
62. Kershaw NJ, Murphy JM, Lucet IS, Nicola NA, Babon JJ. Regulation of Janus kinases by SOCS proteins. Biochem Soc Trans (2013) 41:1042-7. doi:10.1042/BST20130077
63. Croker BA, Kiu H, Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol (2008) 19:414-22. doi:10.1016/j.semcdb.2008.07.010
64. Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN, et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity (2012) 36:239-50. doi:10.1016/j.immuni.2011.12.015
65. Yoshimura A, Suzuki M, Sakaguchi R, Hanada T, Yasukawa H. SOCS, inflammation, and autoimmunity. Front Immunol (2012) 3:20. doi:10.3389/fimmu.2012.00020
66. Kershaw NJ, Murphy JM, Liau NP, Varghese LN, Laktyushin A, Whitlock EL, et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol (2013) 20:469-76. doi:10.1038/nsmb.2519
67. Bohmer FD, Friedrich K. Protein tyrosine phosphatases as wardens of STAT signaling. JAKSTAT (2014) 3:e28087. doi:10.4161/jkst.28087
68. Schmidt D, Muller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci U S A (2002) 99:2872-7. doi:10.1073/pnas.052559499
69. Takahashi Y, Toh EA, Kikuchi Y. Comparative analysis of yeast PIAS-type SUMO ligases in vivo and in vitro. J Biochem (2003) 133:415-22. doi:10.1093/jb/mvg054
70. Sharrocks AD. PIAS proteins and transcriptional regulation-more than just SUMO E3 ligases? Genes Dev (2006) 20:754-8. doi:10.1101/gad.1421006
71. Rogers RS, Horvath CM, Matunis MJ. SUMO modification of STAT1 and its role in PIAS-mediated inhibition of gene activation. J Biol Chem (2003) 278:30091-7. doi:10.1074/jbc.M301344200
72. Droescher M, Begitt A, Marg A, Zacharias M, Vinkemeier U. Cytokine-induced paracrystals prolong the activity of signal transducers and activators of transcription (STAT) and provide a model for the regulation of protein solubility by small ubiquitin-like modifier (SUMO). J Biol Chem (2011) 286:18731-46. doi:10.1074/jbc.M111.235978
73. Icardi L, Mori R, Gesellchen V, Eyckerman S, De Cauwer L, Verhelst J, et al. The Sin3a repressor complex is a master regulator of STAT transcriptional activity. Proc Natl Acad Sci U S A (2012) 109:12058-63. doi:10.1073/pnas.1206458109
74. Zhuang S. Regulation of STAT signaling by acetylation. Cell Signal (2013) 25:1924-31. doi:10.1016/j.cellsig.2013.05.007
75. Tang X, Gao JS, Guan YJ, Mclane KE, Yuan ZL, Ramratnam B, et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell (2007) 131:93-105. doi:10.1016/j.cell.2007.07.034
76. Van Nguyen T, Angkasekwinai P, Dou H, Lin FM, Lu LS, Cheng J, et al. SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell (2012) 45:210-21. doi:10.1016/j.molcel.2011.12.026
77. Kosan C, Ginter T, Heinzel T, Kramer OH. STAT5 acetylation: mechanisms and consequences for immunological control and leukemogenesis. JAKSTAT (2013) 2:e26102. doi:10.4161/jkst.26102
78. Biggar KK, Li SS. Non-histone protein methylation as a regulator of cellular signalling and function. Nat Rev Mol Cell Biol (2015) 16:5-17. doi:10.1038/nrm3915
79. Mowen KA, Tang J, Zhu W, Schurter BT, Shuai K, Herschman HR, et al. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell (2001) 104:731-41. doi:10.1016/S0092-8674(01)00269-0
80. Zhu W, Mustelin T, David M. Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase. J Biol Chem (2002) 277:35787-90. doi:10.1074/jbc.C200346200
81. Chen W, Daines MO, Hershey GK. Methylation of STAT6 modulates STAT6 phosphorylation, nuclear translocation, and DNA-binding activity. J Immunol (2004) 172:6744-50. doi:10.4049/jimmunol.172.11.6744
82. Chen K, Liu J, Liu S, Xia M, Zhang X, Han D, et al. Methyltransferase SETD2-mediated methylation of STAT1 is critical for interferon antiviral activity. Cell (2017) 170(492-506):e414. doi:10.1016/j.cell.2017.06.042
83. Yang J, Huang J, Dasgupta M, Sears N, Miyagi M, Wang B, et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A (2010) 107:21499-504. doi:10.1073/pnas.1016147107
84. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 23:839-52. doi:10.1016/j.ccr.2013.04.008
85. Dasgupta M, Unal H, Willard B, Yang J, Karnik SS, Stark GR. Critical role for lysine 685 in gene expression mediated by transcription factor unphosphorylated STAT3. J Biol Chem (2014) 289:30763-71. doi:10.1074/jbc.M114.603894
86. Chen K, Liu J, Cao X. Regulation of type I interferon signaling in immunity and inflammation: a comprehensive review. J Autoimmun (2017) 83:1-11. doi:10.1016/j.jaut.2017.03.008
87. Villarroya-Beltri C, Guerra S, Sanchez-Madrid F. ISGylation-a key to lock the cell gates for preventing the spread of threats. J Cell Sci (2017) 130(18):2961-9. doi:10.1242/jcs.205468
88. Malakhova OA, Yan M, Malakhov MP, Yuan Y, Ritchie KJ, Kim KI, et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev (2003) 17:455-60. doi:10.1101/gad.1056303
89. Przanowski P, Loska S, Cysewski D, Dabrowski M, Kaminska B. ISG'ylation increases stability of numerous proteins including Stat1, which prevents premature termination of immune response in LPS-stimulated microglia. Neurochem Int (2017). doi:10.1016/j.neuint.2017.07.013
90. Kumar P, Gogulamudi VR, Peryasamy R, Raghavaraju G, Subramania U, Pandey KN. Inhibition of HDAC enhances STAT acetylation, blocks NF-KappaB, and suppresses the renal inflammation and fibrosis in Npr1 haplotype male mice. Am J Physiol Renal Physiol (2017) 313(3):F781-95. doi:10.1152/ajprenal.00166.2017
91. Li J, Chen F, Zheng M, Zhu H, Zhao D, Liu W, et al. Inhibition of STAT1 methylation is involved in the resistance of hepatitis B virus to Interferon alpha. Antiviral Res (2010) 85:463-9. doi:10.1016/j.antiviral.2009.10.011
92. Moon J, Kaowinn S, Cho IR, Min DS, Myung H, Oh S, et al. Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4. Biochem Biophys Res Commun (2016) 474:428-34. doi:10.1016/j.bbrc.2016.05.005
93. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol (2014) 15:509-24. doi:10.1038/nrm3838
94. Liu F, Du Y, Feng WH. New perspective of host microRNAs in the control of PRRSV infection. Vet Microbiol (2017) 209:48-56. doi:10.1016/j.vetmic.2017.01.004
95. Smith S, Fernando T, Wu PW, Seo J, Ni Gabhann J, Piskareva O, et al. MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. J Autoimmun (2017) 79:105-11. doi:10.1016/j.jaut.2017.03.003
96. Jia X, Bi Y, Li J, Xie Q, Yang H, Liu W. Cellular microRNA miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by activating innate antiviral immunity. Sci Rep (2015) 5:10651. doi:10.1038/srep10651
97. Li L, Wei Z, Zhou Y, Gao F, Jiang Y, Yu L, et al. Host miR-26a suppresses replication of porcine reproductive and respiratory syndrome virus by upregulating type I interferons. Virus Res (2015) 195:86-94. doi:10.1016/j.virusres.2014.08.012
98. Stickel N, Hanke K, Marschner D, Prinz G, Kohler M, Melchinger W, et al. MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. Leukemia (2017) 31:2732-41. doi:10.1038/leu.2017.137
99. Wang Y, Han Z, Fan Y, Zhang J, Chen K, Gao L, et al. MicroRNA-9 inhibits NLRP3 inflammasome activation in human atherosclerosis inflammation cell models through the JAK1/STAT signaling pathway. Cell Physiol Biochem (2017) 41:1555-71. doi:10.1159/000470822
100. Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, et al. Direct upregulation of STAT3 by microRNA-551b-3p deregulates growth and metastasis of ovarian cancer. Cell Rep (2016) 15:1493-504. doi:10.1016/j.celrep.2016.04.034
101. Jarret A, Mcfarland AP, Horner SM, Kell A, Schwerk J, Hong M, et al. Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. Nat Med (2016) 22:1475-81. doi:10.1038/nm.4211
102. Zhang Y, Yang L, Wang H, Zhang G, Sun X. Respiratory syncytial virus non-structural protein 1 facilitates virus replication through miR-29a-mediated inhibition of interferon-alpha receptor. Biochem Biophys Res Commun (2016) 478:1436-41. doi:10.1016/j.bbrc.2016.08.142
103. Mukherjee A, Di Bisceglie AM, Ray RB. Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway. J Virol (2015) 89:3356-65. doi:10.1128/JVI.03085-14
104. Zhang Q, Huang C, Yang Q, Gao L, Liu HC, Tang J, et al. MicroRNA-30c modulates type I IFN responses to facilitate porcine reproductive and respiratory syndrome virus infection by targeting JAK1. J Immunol (2016) 196:2272-82. doi:10.4049/jimmunol.1502006
105. Wang L, Li L, Guo R, Li X, Lu Y, Guan X, et al. miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2. Cell Physiol Biochem (2014) 34:413-22. doi:10.1159/000363010
106. Wang S, Chen X, Tang M. MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2. Oncol Rep (2014) 32:2824-30. doi:10.3892/or.2014.3478
107. Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH. MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One (2010) 5:e8836. doi:10.1371/journal.pone.0008836
108. Wang S, Zhang X, Ju Y, Zhao B, Yan X, Hu J, et al. MicroRNA-146a feedback suppresses T cell immune function by targeting Stat1 in patients with chronic hepatitis B. J Immunol (2013) 191:293-301. doi:10.4049/jimmunol.1202100
109. Moles R, Bellon M, Nicot C. STAT1: a novel target of miR-150 and miR-223 is involved in the proliferation of HTLV-I-transformed and ATL cells. Neoplasia (2015) 17:449-62. doi:10.1016/j.neo.2015.04.005
110. Dernowsek JA, Pereira MC, Fornari TA, Macedo C, Assis AF, Donate PB, et al. Posttranscriptional interaction between miR-450a-5p and miR-28-5p and STAT1 mRNA triggers osteoblastic differentiation of human mesenchymal stem cells. J Cell Biochem (2017) 118(11):4045-62. doi:10.1002/jcb.26060
111. Zhang C, Han L, Zhang A, Yang W, Zhou X, Pu P, et al. Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells. Int J Oncol (2010) 36:1503-12. doi:10.3892/ijo_00000637
112. Koukos G, Polytarchou C, Kaplan JL, Morley-Fletcher A, Gras-Miralles B, Kokkotou E, et al. MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis. Gastroenterology (2013) 145(842-852):e842. doi:10.1053/j.gastro.2013.07.001
113. Huang Y, Lei Y, Zhang H, Hou L, Zhang M, Dayton AI. MicroRNA regulation of STAT4 protein expression: rapid and sensitive modulation of IL-12 signaling in human natural killer cells. Blood (2011) 118:6793-802. doi:10.1182/blood-2011-05-356162
114. Leoncini PP, Bertaina A, Papaioannou D, Flotho C, Masetti R, Bresolin S, et al. MicroRNA-150 regulates STAT5b levels in juvenile myelomonocytic leukemia (JMML). Am Soc Hematol (2015) 126(23):2851
115. Peng HY, Jiang SS, Hsiao JR, Hsiao M, Hsu YM, Wu GH, et al. IL-8 induces miR-424-5p expression and modulates SOCS2/STAT5 signaling pathway in oral squamous cell carcinoma. Mol Oncol (2016) 10:895-909. doi:10.1016/j.molonc.2016.03.001
116. Gao D, Zhai A, Qian J, Li A, Li Y, Song W, et al. Down-regulation of suppressor of cytokine signaling 3 by miR-122 enhances interferon-mediated suppression of hepatitis B virus. Antiviral Res (2015) 118:20-8. doi:10.1016/j.antiviral.2015.03.001
117. Kambara H, Niazi F, Kostadinova L, Moonka DK, Siegel CT, Post AB, et al. Negative regulation of the interferon response by an interferon-induced long non-coding RNA. Nucleic Acids Res (2014) 42:10668-80. doi:10.1093/nar/gku713
118. Witte S, Muljo SA. Integrating non-coding RNAs in JAK-STAT regulatory networks. JAKSTAT (2014) 3:e28055. doi:10.4161/jkst.28055
119. Carpenter S. Editorial: functions of non-coding RNA in innate immunity. Front Immunol (2015) 6:622. doi:10.3389/fimmu.2015.00622
120. Ouyang J, Hu J, Chen JL. lncRNAs regulate the innate immune response to viral infection. Wiley Interdiscip Rev RNA (2016) 7:129-43. doi:10.1002/wrna.1321
121. Symons JA, Alcami A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell (1995) 81:551-60. doi:10.1016/0092-8674(95)90076-4
122. Alcami A, Symons JA, Smith GL. The Vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol (2000) 74:11230-9. doi:10.1128/JVI.74.23.11230-11239.2000
123. Johnson KE, Knipe DM. Herpes simplex virus-1 infection causes the secretion of a type I interferon-antagonizing protein and inhibits signaling at or before Jak-1 activation. Virology (2010) 396:21-9. doi:10.1016/j.virol.2009.09.021
124. Yokota S, Saito H, Kubota T, Yokosawa N, Amano K, Fujii N. Measles virus suppresses interferon-alpha signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-alpha receptor complex. Virology (2003) 306:135-46. doi:10.1016/S0042-6822(02)00026-0
125. Bisson SA, Page AL, Ganem D. A Kaposi's sarcoma-associated herpesvirus protein that forms inhibitory complexes with type I interferon receptor subunits, Jak and STAT proteins, and blocks interferon-mediated signal transduction. J Virol (2009) 83:5056-66. doi:10.1128/JVI.02516-08
126. Shah KM, Stewart SE, Wei W, Woodman CB, O'neil JD, Dawson CW, et al. The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. Oncogene (2009) 28:3903-14. doi:10.1038/onc.2009.249
127. Jia D, Rahbar R, Chan RW, Lee SM, Chan MC, Wang BX, et al. Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling. PLoS One (2010) 5:e13927. doi:10.1371/journal.pone.0013927
128. Miller DM, Rahill BM, Boss JM, Lairmore MD, Durbin JE, Waldman JW, et al. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med (1998) 187:675-83. doi:10.1084/jem.187.5.675
129. Chee AV, Roizman B. Herpes simplex virus 1 gene products occlude the interferon signaling pathway at multiple sites. J Virol (2004) 78:4185-96. doi:10.1128/JVI.78.8.4185-4196.2004
130. Leonard GT, Sen GC. Effects of adenovirus E1A protein on interferon-signaling. Virology (1996) 224:25-33. doi:10.1006/viro.1996.0503
131. Lin W, Choe WH, Hiasa Y, Kamegaya Y, Blackard JT, Schmidt EV, et al. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology (2005) 128:1034-41. doi:10.1053/j.gastro.2005.02.006
132. Stevenson NJ, Bourke NM, Ryan EJ, Binder M, Fanning L, Johnston JA, et al. Hepatitis C virus targets the interferon-alpha JAK/STAT pathway by promoting proteasomal degradation in immune cells and hepatocytes. FEBS Lett (2013) 587:1571-8. doi:10.1016/j.febslet.2013.03.041
133. Guo L, Luo X, Li R, Xu Y, Zhang J, Ge J, et al. Porcine epidemic diarrhea virus infection inhibits interferon signaling by targeted degradation of STAT1. J Virol (2016) 90:8281-92. doi:10.1128/JVI.01091-16
134. Fleming SB. Viral inhibition of the IFN-induced JAK/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists. Vaccines (Basel) (2016) 4(3):E23. doi:10.3390/vaccines4030023
135. Parisien JP, Lau JF, Rodriguez JJ, Sullivan BM, Moscona A, Parks GD, et al. The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2. Virology (2001) 283:230-9. doi:10.1006/viro.2001.0856
136. Andrejeva J, Young DF, Goodbourn S, Randall RE. Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: consequences for virus replication in the presence of alpha/beta and gamma interferons. J Virol (2002) 76:2159-67. doi:10.1128/jvi.76.5.2159-2167.2002
137. Precious B, Childs K, Fitzpatrick-Swallow V, Goodbourn S, Randall RE. Simian virus 5 V protein acts as an adaptor, linking DDB1 to STAT2, to facilitate the ubiquitination of STAT1. J Virol (2005) 79:13434-41. doi:10.1128/JVI.79.21.13434-13441.2005
138. Precious B, Young DF, Andrejeva L, Goodbourn S, Randall RE. In vitro and in vivo specificity of ubiquitination and degradation of STAT1 and STAT2 by the V proteins of the paramyxoviruses simian virus 5 and human parainfluenza virus type 2. J Gen Virol (2005) 86:151-8. doi:10.1099/vir.0.80263-0
139. Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A. NS5 of dengue virus mediates STAT2 binding and degradation. J Virol (2009) 83:5408-18. doi:10.1128/JVI.02188-08
140. Grant A, Ponia SS, Tripathi S, Balasubramaniam V, Miorin L, Sourisseau M, et al. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe (2016) 19:882-90. doi:10.1016/j.chom.2016.05.009
141. Dar HA, Zaheer T, Paracha RZ, Ali A. Structural analysis and insight into Zika virus NS5 mediated interferon inhibition. Infect Genet Evol (2017) 51:143-52. doi:10.1016/j.meegid.2017.03.027
142. Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JF, et al. Respiratory syncytial virus NS1 protein degrades STAT2 by using the elongin-cullin E3 ligase. J Virol (2007) 81:3428-36. doi:10.1128/JVI.02303-06
143. Zhu X, Wang D, Zhou J, Pan T, Chen J, Yang Y, et al. Porcine deltacoronavirus nsp5 antagonizes type I interferon signaling by cleaving STAT2. J Virol (2017) 91(10):e00003-17. doi:10.1128/JVI.00003-17
144. Arnold MM, Barro M, Patton JT. Rotavirus NSP1 mediates degradation of interferon regulatory factors through targeting of the dimerization domain. J Virol (2013) 87:9813-21. doi:10.1128/JVI.01146-13
145. Verweij MC, Wellish M, Whitmer T, Malouli D, Lapel M, Jonjic S, et al. Varicella viruses inhibit interferon-stimulated JAK-STAT signaling through multiple mechanisms. PLoS Pathog (2015) 11:e1004901. doi:10.1371/journal.ppat.1004901
146. Miller DM, Zhang Y, Rahill BM, Waldman WJ, Sedmak DD. Human cytomegalovirus inhibits IFN-alpha-stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-alpha signal transduction. J Immunol (1999) 162:6107-13
147. Li S, Labrecque S, Gauzzi MC, Cuddihy AR, Wong AH, Pellegrini S, et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene (1999) 18:5727-37. doi:10.1038/sj.onc.1202960
148. Takeuchi K, Kadota SI, Takeda M, Miyajima N, Nagata K. Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett (2003) 545:177-82. doi:10.1016/S0014-5793(03)00528-3
149. Caignard G, Guerbois M, Labernardiere JL, Jacob Y, Jones LM, Wild F, et al. Measles virus V protein blocks Jak1-mediated phosphorylation of STAT1 to escape IFN-alpha/beta signaling. Virology (2007) 368:351-62. doi:10.1016/j.virol.2007.06.037
150. Oda K, Matoba Y, Irie T, Kawabata R, Fukushi M, Sugiyama M, et al. Structural basis of the inhibition of STAT1 activity by sendai virus c protein. J Virol (2015) 89:11487-99. doi:10.1128/JVI.01887-15
151. Garcin D, Marq JB, Strahle L, Le Mercier P, Kolakofsky D. All four Sendai virus C proteins bind Stat1, but only the larger forms also induce its mono-ubiquitination and degradation. Virology (2002) 295:256-65. doi:10.1006/viro.2001.1342
152. Ning YJ, Feng K, Min YQ, Cao WC, Wang M, Deng F, et al. Disruption of type I interferon signaling by the nonstructural protein of severe fever with thrombocytopenia syndrome virus via the hijacking of STAT2 and STAT1 into inclusion bodies. J Virol (2015) 89:4227-36. doi:10.1128/JVI.00154-15
153. Zhang AP, Bornholdt ZA, Liu T, Abelson DM, Lee DE, Li S, et al. The Ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog (2012) 8:e1002550. doi:10.1371/journal.ppat.1002550
154. Senft AP, Taylor RH, Lei W, Campbell SA, Tipper JL, Martinez MJ, et al. Respiratory syncytial virus impairs macrophage IFN-alpha/beta-and IFN-gamma-stimulated transcription by distinct mechanisms. Am J Respir Cell Mol Biol (2010) 42:404-14. doi:10.1165/rcmb.2008-0229OC
155. Valmas C, Grosch MN, Schumann M, Olejnik J, Martinez O, Best SM, et al. Marburg virus evades interferon responses by a mechanism distinct from Ebola virus. PLoS Pathog (2010) 6:e1000721. doi:10.1371/journal.ppat.1000721
156. Lin RJ, Liao CL, Lin E, Lin YL. Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese encephalitis virus infection. J Virol (2004) 78:9285-94. doi:10.1128/JVI.78.17.9285-9294.2004
157. Best SM, Morris KL, Shannon JG, Robertson SJ, Mitzel DN, Park GS, et al. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J Virol (2005) 79:12828-39. doi:10.1128/JVI.79.20.12828-12839.2005
158. Guo JT, Hayashi J, Seeger C. West Nile virus inhibits the signal transduction pathway of alpha interferon. J Virol (2005) 79:1343-50. doi:10.1128/JVI.79.3.1343-1350.2005
159. Ho LJ, Hung LF, Weng CY, Wu WL, Chou P, Lin YL, et al. Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell. J Immunol (2005) 174:8163-72. doi:10.4049/jimmunol.174.12.8163
160. Kumthip K, Chusri P, Jilg N, Zhao L, Fusco DN, Zhao H, et al. Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol (2012) 86:8581-91. doi:10.1128/JVI.00533-12
161. Shanker V, Trincucci G, Heim HM, Duong HT. Protein phosphatase 2A impairs IFNalpha-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation. J Viral Hepat (2013) 20:612-21. doi:10.1111/jvh.12083
162. Sen A, Rott L, Phan N, Mukherjee G, Greenberg HB. Rotavirus NSP1 protein inhibits interferon-mediated STAT1 activation. J Virol (2014) 88:41-53. doi:10.1128/JVI.01501-13
163. Najarro P, Traktman P, Lewis JA. Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation. J Virol (2001) 75:3185-96. doi:10.1128/JVI.75.7.3185-3196.2001
164. Koksal AC, Cingolani G. Dimerization of Vaccinia virus VH1 is essential for dephosphorylation of STAT1 at tyrosine 701. J Biol Chem (2011) 286:14373-82. doi:10.1074/jbc.M111.226357
165. Hakes DJ, Martell KJ, Zhao WG, Massung RF, Esposito JJ, Dixon JE. A protein phosphatase related to the Vaccinia virus VH1 is encoded in the genomes of several orthopoxviruses and a baculovirus. Proc Natl Acad Sci U S A (1993) 90:4017-21. doi:10.1073/pnas.90.9.4017
166. Tropea JE, Phan J, Waugh DS. Overproduction, purification, and biochemical characterization of the dual specificity H1 protein phosphatase encoded by variola major virus. Protein Expr Purif (2006) 50:31-6. doi:10.1016/j.pep.2006.05.007
167. Johnson KE, Song B, Knipe DM. Role for herpes simplex virus 1 ICP27 in the inhibition of type I interferon signaling. Virology (2008) 374:487-94. doi:10.1016/j.virol.2008.01.001
168. Vidy A, Chelbi-Alix M, Blondel D. Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. J Virol (2005) 79:14411-20. doi:10.1128/JVI.79.22.14411-14420.2005
169. Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 80:5156-67. doi:10.1128/JVI.02349-05
170. Ding JN, Zhang YJ, Zhong H, Ao CC, Li J, Han JG. An all-atom molecular dynamics study of the anti-interferon signaling of Ebola virus: interaction mechanisms of EBOV VP24 binding to Karyopherin alpha5. Mol Biosyst (2017) 13:1031-45. doi:10.1039/c7mb00136c
171. Schwarz TM, Edwards MR, Diederichs A, Alinger JB, Leung DW, Amarasinghe GK, et al. VP24-karyopherin alpha binding affinities differ between Ebolavirus species, influencing interferon inhibition and VP24 stability. J Virol (2017) 91(4):e1715-6. doi:10.1128/JVI.01715-16
172. Patel D, Nan Y, Shen M, Ritthipichai K, Zhu X, Zhang YJ. Porcine reproductive and respiratory syndrome virus inhibits type I interferon signaling by blocking STAT1/STAT2 nuclear translocation. J Virol (2010) 84:11045-55. doi:10.1128/JVI.00655-10
173. Wang R, Nan Y, Yu Y, Zhang YJ. Porcine reproductive and respiratory syndrome virus Nsp1beta inhibits interferon-activated JAK/STAT signal transduction by inducing karyopherin-alpha1 degradation. J Virol (2013) 87:5219-28. doi:10.1128/JVI.02643-12
174. Du Y, Bi J, Liu J, Liu X, Wu X, Jiang P, et al. 3Cpro of foot-and-mouth disease virus antagonizes the interferon signaling pathway by blocking STAT1/STAT2 nuclear translocation. J Virol (2014) 88:4908-20. doi:10.1128/JVI.03668-13
175. Wang C, Sun M, Yuan X, Ji L, Jin Y, Cardona CJ, et al. Enterovirus 71 suppresses interferon responses by blocking Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling through inducing karyopherin-alpha1 degradation. J Biol Chem (2017) 292:10262-74. doi:10.1074/jbc.M116.745729
176. Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology (1999) 259:305-13. doi:10.1006/viro.1999.9771
177. Zurney J, Kobayashi T, Holm GH, Dermody TS, Sherry B. Reovirus mu2 protein inhibits interferon signaling through a novel mechanism involving nuclear accumulation of interferon regulatory factor 9. J Virol (2009) 83:2178-87. doi:10.1128/JVI.01787-08
178. Zhang R, Fang L, Wang D, Cai K, Zhang H, Xie L, et al. Porcine bocavirus NP1 negatively regulates interferon signaling pathway by targeting the DNA-binding domain of IRF9. Virology (2015) 485:414-21. doi:10.1016/j.virol.2015.08.005
179. Zhang J, Yamada O, Kawagishi K, Araki H, Yamaoka S, Hattori T, et al. Human T-cell leukemia virus type 1 Tax modulates interferon-alpha signal transduction through competitive usage of the coactivator CBP/p300. Virology (2008) 379:306-13. doi:10.1016/j.virol.2008.06.035
180. Xing J, Ni L, Wang S, Wang K, Lin R, Zheng C. Herpes simplex virus 1-encoded tegument protein VP16 abrogates the production of beta interferon (IFN) by inhibiting NF-kappaB activation and blocking IFN regulatory factor 3 to recruit its coactivator CBP. J Virol (2013) 87:9788-801. doi:10.1128/JVI.01440-13
181. de Lucas S, Bartolome J, Carreno V. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis (2005) 191:93-9. doi:10.1086/426509
182. Papadopoulou AS, Dooley J, Linterman MA, Pierson W, Ucar O, Kyewski B, et al. The thymic epithelial microRNA network elevates the threshold for infection-associated thymic involution via miR-29a mediated suppression of the IFN-alpha receptor. Nat Immunol (2011) 13:181-7. doi:10.1038/ni.2193
183. Li Y, Xie J, Xu X, Wang J, Ao F, Wan Y, et al. MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-lambda1. Protein Cell (2013) 4:130-41. doi:10.1007/s13238-012-2081-y
184. Gao S, Li J, Song L, Wu J, Huang W. Influenza A virus-induced downregulation of miR-26a contributes to reduced IFNalpha/beta production. Virol Sin (2017) 32(4):261-70. doi:10.1007/s12250-017-4004-9
185. Hou J, Wang P, Lin L, Liu X, Ma F, An H, et al. MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol (2009) 183:2150-8. doi:10.4049/jimmunol.0900707
186. Liang D, Gao Y, Lin X, He Z, Zhao Q, Deng Q, et al. A human herpesvirus miRNA attenuates interferon signaling and contributes to maintenance of viral latency by targeting IKKepsilon. Cell Res (2011) 21:793-806. doi:10.1038/cr.2011.5
187. Silva LF, Jones C. Two microRNAs encoded within the bovine herpesvirus 1 latency-related gene promote cell survival by interacting with RIG-I and stimulating NF-kappaB-dependent transcription and beta interferon signaling pathways. J Virol (2012) 86:1670-82. doi:10.1128/JVI.06550-11
188. Hooykaas MJG, Van Gent M, Soppe JA, Kruse E, Boer IGJ, Van Leenen D, et al. EBV microRNA BART16 suppresses type I IFN signaling. J Immunol (2017) 198:4062-73. doi:10.4049/jimmunol.1501605
189. Akhtar LN, Benveniste EN. Viral exploitation of host SOCS protein functions. J Virol (2011) 85:1912-21. doi:10.1128/JVI.01857-10
190. Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J (2003) 17:488-90. doi:10.1096/fj.02-0664fje
191. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology (2007) 46:1009-15. doi:10.1002/hep.21782
192. Pauli EK, Schmolke M, Wolff T, Viemann D, Roth J, Bode JG, et al. Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog (2008) 4:e1000196. doi:10.1371/journal.ppat.1000196
193. Moore EC, Barber J, Tripp RA. Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol J (2008) 5:116. doi:10.1186/1743-422X-5-116
194. Akhtar LN, Qin H, Muldowney MT, Yanagisawa LL, Kutsch O, Clements JE, et al. Suppressor of cytokine signaling 3 inhibits antiviral IFN-beta signaling to enhance HIV-1 replication in macrophages. J Immunol (2010) 185:2393-404. doi:10.4049/jimmunol.0903563
195. Frey KG, Ahmed CM, Dabelic R, Jager LD, Noon-Song EN, Haider SM, et al. HSV-1-induced SOCS-1 expression in keratinocytes: use of a SOCS-1 antagonist to block a novel mechanism of viral immune evasion. J Immunol (2009) 183:1253-62. doi:10.4049/jimmunol.0900570
196. Tsunematsu S, Suda G, Yamasaki K, Kimura M, Izumi T, Umemura M, et al. Hepatitis B virus X protein impairs alpha-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A. J Med Virol (2017) 89:267-75. doi:10.1002/jmv.24643
197. Mahony R, Gargan S, Roberts KL, Bourke N, Keating SE, Bowie AG, et al. A novel anti-viral role for STAT3 in IFN-alpha signalling responses. Cell Mol Life Sci (2017) 74:1755-64. doi:10.1007/s00018-016-2435-3
198. Yang L, Wang R, Ma Z, Xiao Y, Nan Y, Wang Y, et al. Porcine reproductive and respiratory syndrome virus antagonizes JAK/STAT3 signaling via nsp5, which induces STAT3 degradation. J Virol (2017) 91(3):e2087-2016. doi:10.1128/JVI.02087-16
199. Hsia HC, Stopford CM, Zhang Z, Damania B, Baldwin AS. Signal transducer and activator of transcription 3 (Stat3) regulates host defense and protects mice against herpes simplex virus-1 (HSV-1) infection. J Leukoc Biol (2017) 101:1053-64. doi:10.1189/jlb.4A1016-199RR
200. Kuchipudi SV. The complex role of STAT3 in viral infections. J Immunol Res (2015) 2015:272359. doi:10.1155/2015/272359
201. Mitzel DN, Jaramillo RJ, Stout-Delgado H, Senft AP, Harrod KS. Human metapneumovirus inhibits the IL-6-induced JAK/STAT3 signalling cascade in airway epithelium. J Gen Virol (2014) 95:26-37. doi:10.1099/vir.0.055632-0
202. Mizutani T, Fukushi S, Murakami M, Hirano T, Saijo M, Kurane I, et al. Tyrosine dephosphorylation of STAT3 in SARS coronavirus-infected Vero E6 cells. FEBS Lett (2004) 577:187-92. doi:10.1016/j.febslet.2004.10.005
203. Reitsma JM, Sato H, Nevels M, Terhune SS, Paulus C. Human cytomegalovirus IE1 protein disrupts interleukin-6 signaling by sequestering STAT3 in the nucleus. J Virol (2013) 87:10763-76. doi:10.1128/JVI.01197-13
204. Ulane CM, Rodriguez JJ, Parisien JP, Horvath CM. STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J Virol (2003) 77:6385-93. doi:10.1128/JVI.77.11.6385-6393.2003
205. Puri M, Lemon K, Duprex WP, Rima BK, Horvath CM. A point mutation, E95D, in the mumps virus V protein disengages STAT3 targeting from STAT1 targeting. J Virol (2009) 83:6347-56. doi:10.1128/JVI.00596-09
206. Palosaari H, Parisien JP, Rodriguez JJ, Ulane CM, Horvath CM. STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. J Virol (2003) 77:7635-44. doi:10.1128/JVI.77.13.7635-7644.2003
207. Lieu KG, Brice A, Wiltzer L, Hirst B, Jans DA, Blondel D, et al. The rabies virus interferon antagonist P protein interacts with activated STAT3 and inhibits Gp130 receptor signaling. J Virol (2013) 87:8261-5. doi:10.1128/JVI.00989-13
208. Zhao LJ, He SF, Wang W, Ren H, Qi ZT. Interferon alpha antagonizes STAT3 and SOCS3 signaling triggered by hepatitis C virus. Cytokine (2016) 80:48-55. doi:10.1016/j.cyto.2015.08.264
209. Tanabe Y, Nishibori T, Su L, Arduini RM, Baker DP, David M. Cutting edge: role of STAT1, STAT3, and STAT5 in IFN-alpha beta responses in T lymphocytes. J Immunol (2005) 174:609-13. doi:10.4049/jimmunol.174.2.609
210. Gestermann N, Mekinian A, Comets E, Loiseau P, Puechal X, Hachulla E, et al. STAT4 is a confirmed genetic risk factor for Sjogren's syndrome and could be involved in type 1 interferon pathway signaling. Genes Immun (2010) 11:432-8. doi:10.1038/gene.2010.38
211. Hsu YA, Huang CC, Kung YJ, Lin HJ, Chang CY, Lee KR, et al. The anti-proliferative effects of type I IFN involve STAT6-mediated regulation of SP1 and BCL6. Cancer Lett (2016) 375:303-12. doi:10.1016/j.canlet.2016.02.047
212. Zhao K, Zhang Q, Li X, Zhao D, Liu Y, Shen Q, et al. Cytoplasmic STAT4 promotes antiviral type I IFN production by blocking CHIP-mediated degradation of RIG-I. J Immunol (2016) 196:1209-17. doi:10.4049/jimmunol.1501224
213. Jiang DK, Wu X, Qian J, Ma XP, Yang J, Li Z, et al. Genetic variation in STAT4 predicts response to interferon-alpha therapy for hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2016) 63:1102-11. doi:10.1002/hep.28423
214. Bente DA, Alimonti JB, Shieh WJ, Camus G, Stroher U, Zaki S, et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol (2010) 84:11089-100. doi:10.1128/JVI.01383-10
215. Bradfute SB, Stuthman KS, Shurtleff AC, Bavari S. A STAT-1 knockout mouse model for Machupo virus pathogenesis. Virol J (2011) 8:300. doi:10.1186/1743-422X-8-300
216. Yun NE, Seregin AV, Walker DH, Popov VL, Walker AG, Smith JN, et al. Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus. J Virol (2013) 87:10908-11. doi:10.1128/JVI.01433-13
217. Ortego J, De La Poza F, Marin-Lopez A. Interferon alpha/beta receptor knockout mice as a model to study bluetongue virus infection. Virus Res (2014) 182:35-42. doi:10.1016/j.virusres.2013.09.038
218. Lindqvist R, Mundt F, Gilthorpe JD, Wolfel S, Gekara NO, Kroger A, et al. Fast type I interferon response protects astrocytes from flavivirus infection and virus-induced cytopathic effects. J Neuroinflammation (2016) 13:277. doi:10.1186/s12974-016-0748-7
219. Devaux P, Hudacek AW, Hodge G, Reyes-Del Valle J, Mcchesney MB, Cattaneo R. A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys. J Virol (2011) 85:348-56. doi:10.1128/JVI.00802-10
220. Simmons JD, Wollish AC, Heise MT. A determinant of Sindbis virus neurovirulence enables efficient disruption of Jak/STAT signaling. J Virol (2010) 84:11429-39. doi:10.1128/JVI.00577-10
221. Laurent-Rolle M, Boer EF, Lubick KJ, Wolfinbarger JB, Carmody AB, Rockx B, et al. The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling. J Virol (2010) 84:3503-15. doi:10.1128/JVI.01161-09
222. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 252:324-30. doi:10.1006/viro.1998.9508
223. Wang L, Suarez DL, Pantin-Jackwood M, Mibayashi M, Garcia-Sastre A, Saif YM, et al. Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry. Vaccine (2008) 26:3580-6. doi:10.1016/j.vaccine.2008.05.001
224. Talon J, Salvatore M, O'neill RE, Nakaya Y, Zheng H, Muster T, et al. Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. Proc Natl Acad Sci U S A (2000) 97:4309-14. doi:10.1073/pnas.070525997
225. Hai R, Martinez-Sobrido L, Fraser KA, Ayllon J, Garcia-Sastre A, Palese P. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol (2008) 82:10580-90. doi:10.1128/JVI.01213-08
226. Solorzano A, Webby RJ, Lager KM, Janke BH, Garcia-Sastre A, Richt JA. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol (2005) 79:7535-43. doi:10.1128/JVI.79.12.7535-7543.2005
227. Baskin CR, Bielefeldt-Ohmann H, Garcia-Sastre A, Tumpey TM, Van Hoeven N, Carter VS, et al. Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J Virol (2007) 81:11817-27. doi:10.1128/JVI.02223-07
228. Vincent AL, Ma W, Lager KM, Janke BH, Webby RJ, Garcia-Sastre A, et al. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine (2007) 25:7999-8009. doi:10.1016/j.vaccine.2007.09.019
229. Steel J, Lowen AC, Pena L, Angel M, Solorzano A, Albrecht R, et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol (2009) 83:1742-53. doi:10.1128/JVI.01920-08
230. Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, et al. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1. J Infect Dis (2010) 201:354-62. doi:10.1086/649428
231. Liang JJ, Liao CL, Liao JT, Lee YL, Lin YL. A Japanese encephalitis virus vaccine candidate strain is attenuated by decreasing its interferon antagonistic ability. Vaccine (2009) 27:2746-54. doi:10.1016/j.vaccine.2009.03.007
232. Nan Y, Wu C, Gu G, Sun W, Zhang YJ, Zhou EM. Improved vaccine against PRRSV: current progress and future perspective. Front Microbiol (2017) 8:1635. doi:10.3389/fmicb.2017.01635
233. Beura LK, Subramaniam S, Vu HL, Kwon B, Pattnaik AK, Osorio FA. Identification of amino acid residues important for anti-IFN activity of porcine reproductive and respiratory syndrome virus non-structural protein 1. Virology (2012) 433:431-9. doi:10.1016/j.virol.2012.08.034
234. Sun Z, Li Y, Ransburgh R, Snijder EJ, Fang Y. Nonstructural protein 2 of porcine reproductive and respiratory syndrome virus inhibits the antiviral function of interferon-stimulated gene 15. J Virol (2012) 86:3839-50. doi:10.1128/JVI.06466-11
235. McLaren J, Rowe M, Brennan P. Epstein-Barr virus induces a distinct form of DNA-bound STAT1 compared with that found in interferon-stimulated B lymphocytes. J Gen Virol (2007) 88:1876-86. doi:10.1099/vir.0.82741-0
236. Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD. STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood (2008) 111:2062-72. doi:10.1182/blood-2007-05-091207
237. Wang R, Zhang YJ. Antagonizing interferon-mediated immune response by porcine reproductive and respiratory syndrome virus. Biomed Res Int (2014) 2014:315470. doi:10.1155/2014/315470
238. Yang L, Zhang YJ. Antagonizing cytokine-mediated JAK-STAT signaling by porcine reproductive and respiratory syndrome virus. Vet Microbiol (2016) 209:57-65. doi:10.1016/j.vetmic.2016.12.036
239. Lunney JK, Fang Y, Ladinig A, Chen N, Li Y, Rowland B, et al. Porcine reproductive and respiratory syndrome virus (PRRSV): pathogenesis and interaction with the immune system. Annu Rev Anim Biosci (2016) 4:129-54. doi:10.1146/annurev-animal-022114-111025
240. Xiao S, Mo D, Wang Q, Jia J, Qin L, Yu X, et al. Aberrant host immune response induced by highly virulent PRRSV identified by digital gene expression tag profiling. BMC Genomics (2010) 11:544. doi:10.1186/1471-2164-11-544
241. King CA. Kaposi's sarcoma-associated herpesvirus kaposin B induces unique monophosphorylation of STAT3 at serine 727 and MK2-mediated inactivation of the STAT3 transcriptional repressor TRIM28. J Virol (2013) 87:8779-91. doi:10.1128/JVI.02976-12
242. McCormick C, Ganem D. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science (2005) 307:739-41. doi:10.1126/science.1105779
243. Douam F, Albrecht YES, Hrebikova G, Sadimin E, Davidson C, Kotenko SV, et al. Type III interferon-mediated signaling is critical for controlling live attenuated yellow fever virus infection in vivo. MBio (2017) 8:e819-817. doi:10.1128/mBio.00819-17
244. Yin X, Li X, Ambardekar C, Hu Z, Lhomme S, Feng Z. Hepatitis E virus persists in the presence of a type III interferon response. PLoS Pathog (2017) 13:e1006417. doi:10.1371/journal.ppat.1006417
245. Snell LM, Mcgaha TL, Brooks DG. Type I interferon in chronic virus infection and cancer. Trends Immunol (2017) 38:542-57. doi:10.1016/j.it.2017.05.005
246. Li Y, Li S, Duan X, Liu B, Yang C, Zeng P, et al. Activation of endogenous type I IFN signaling contributes to persistent HCV infection. Rev Med Virol (2014) 24:332-42. doi:10.1002/rmv.1795
247. Murira A, Lamarre A. Type-I interferon responses: from friend to foe in the battle against chronic viral infection. Front Immunol (2016) 7:609. doi:10.3389/fimmu.2016.00609